On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted favorably on six of seven research peptides, including BPC-157, TB-500, Semax and MOTS-c. Coverage since then has called it everything from an approval to a ban. It was neither. Here is what the committee actually did, what FDA staff had recommended going in, and what still has to happen before anything changes.
What Happened on July 23 and 24, 2026
The FDA's Pharmacy Compounding Advisory Committee, usually shortened to PCAC, met over two days to review seven peptides nominated for possible addition to the 503A Bulks List. That list defines which bulk drug substances licensed compounding pharmacies may use when preparing medications for individual patients under section 503A of the Federal Food, Drug, and Cosmetic Act.
The seven peptides under review were BPC-157, KPV, TB-500, MOTS-c, emideltide (also known as DSIP, or delta sleep-inducing peptide), epitalon and Semax.
The committee voted favorably to recommend adding six of them: BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon. Emideltide, the DSIP entry, was not recommended.
That is where most coverage stopped. The rest of this article is the part that matters more.
What a PCAC Vote Actually Is, and What It Is Not
PCAC is an advisory committee. Advisory committees exist to give the FDA outside expert input on scientific and policy questions. Members are external experts convened to discuss the evidence in public, ask questions of agency reviewers, and register an opinion by vote. They are not FDA decision-makers, and they do not write regulation.
Three things follow directly from that:
- A favorable PCAC vote is a recommendation, not a decision.
- PCAC recommendations are advisory and non-binding. The FDA may accept, modify, or decline them.
- Nothing an advisory committee votes on takes legal effect on the day of the vote.
The committee's charter, membership and meeting materials are published on the FDA's Pharmacy Compounding Advisory Committee page, and the current 503A bulks framework is documented on the FDA's 503A bulk drug substances page. Those are the primary sources worth reading before trusting any secondhand summary, including this one.
The Detail Most Coverage Left Out: FDA Staff Recommended Against All Seven
Before an advisory committee meets, FDA review staff publish briefing documents setting out the agency's own assessment of the substances under discussion. For this meeting, FDA's pre-meeting briefing documents recommended against adding all seven peptides to the 503A Bulks List, citing gaps in characterization, effectiveness and safety data.
So the committee's favorable votes ran counter to the agency's own written position going into the meeting. That is unusual, and it is genuinely newsworthy. It is also the single strongest reason not to read these votes as a settled outcome. The FDA makes the final call, and its reviewers have already put on record why the submitted data did not persuade them.
How the Committee Voted
| Peptide | Committee outcome | Reported tally |
|---|---|---|
| BPC-157 | Favorable, recommend adding | 8 in favor, 6 against, 1 abstention |
| TB-500 | Favorable, recommend adding | 8 in favor, 6 against, 1 abstention |
| KPV | Favorable, recommend adding | 8 in favor, 6 against, 1 abstention |
| MOTS-c | Favorable, recommend adding | Favorable vote recorded; tally not itemized here |
| Semax | Favorable, recommend adding | Favorable vote recorded; tally not itemized here |
| Epitalon | Favorable, recommend adding | Favorable vote recorded; tally not itemized here |
| Emideltide (DSIP) | Not recommended | Rejected |
The margins matter. On the three peptides with reported tallies, a shift of two votes would have reversed the result. These were not consensus endorsements. They were narrow splits on a panel that had just reviewed a staff assessment recommending rejection.
What Still Has to Happen Before Anything Changes
For any of these peptides to be compounded under 503A, the FDA has to complete notice-and-comment rulemaking. In outline, that process runs:
- The FDA weighs the committee's recommendation against its own scientific assessment.
- The agency publishes a proposed rule in the Federal Register.
- A public comment period opens, and interested parties file comments on the record.
- The agency reviews those comments and issues a final rule, which may adopt, modify, or decline the recommendation.
That sequence commonly takes 12 months or more, and the outcome is not predetermined at any step. A favorable advisory vote is an input to stage one. It is not a shortcut past stages two through four.
Until a final rule is published, nothing has changed in what a licensed compounding pharmacy may legally prepare. The regulatory status of BPC-157, TB-500, Semax, MOTS-c, KPV and epitalon on July 26, 2026 is the same as it was on July 22, 2026.
What This Does and Does Not Mean, Peptide by Peptide
BPC-157. A synthetic peptide sequence studied largely in preclinical models for tissue repair and gut signaling. The committee voted to recommend adding it. A final FDA decision is pending. It is not FDA-approved, and its availability has not changed. For background on the science and the review timeline, see the TelosRX BPC-157 patient guide written ahead of this PCAC review, and the accompanying safety and contraindications overview.
TB-500. A thymosin beta-4 related fragment studied preclinically in the context of tissue repair and cell migration. Same picture: a favorable recommendation on a narrow vote, a pending FDA decision, no change in status. Mechanism background is covered in the TelosRX TB-500 research overview.
Semax. A short neuropeptide studied primarily in Russian-language literature for effects on cognitive and neurotrophic signaling. Recommended favorably by the committee, pending at the FDA, unchanged in status. See the TelosRX Semax research overview.
MOTS-c. A mitochondrial-derived peptide studied in metabolic and mitochondrial signaling research. Recommended favorably, pending at the FDA, unchanged in status. See the TelosRX MOTS-c research overview.
All four are research peptides. None of them is FDA-approved for any human use. Where they are available at all, it is by prescription only, after review by a US-licensed provider, and approval is never guaranteed.
How to Read Coverage of This Vote
The fastest way to judge whether a source got this story right is to check the verbs.
| Accurate framing | Inaccurate framing |
|---|---|
| An FDA advisory committee voted to recommend adding these peptides | The FDA approved these peptides |
| A final FDA decision is pending and requires rulemaking | These peptides are now legal |
| The votes were narrow, and FDA staff had recommended against | The FDA endorsed these peptides |
| Availability has not changed | These peptides are newly available |
| Emideltide (DSIP) was not recommended | Peptides were banned at this meeting |
Any source using the language in the right column is either compressing the story badly or selling something. A recommendation from an advisory committee and a decision from a federal agency are not the same event, and the gap between them is measured in months of rulemaking, not days.
Frequently Asked Questions
Did the FDA approve BPC-157, TB-500, Semax or MOTS-c in July 2026?
No. An FDA advisory committee voted to recommend adding them to the 503A Bulks List. That is a recommendation, not an approval, and it is not the same thing as FDA approval of a drug. None of these peptides is FDA-approved for any human use.
What is the Pharmacy Compounding Advisory Committee?
PCAC is a committee of outside experts that advises the FDA on questions related to pharmacy compounding, including which bulk drug substances should be eligible for use in compounding under section 503A. It discusses evidence in public and registers opinions by vote. Its recommendations are advisory and non-binding, and it does not issue regulations.
Does the July 2026 vote change what a pharmacy can legally compound today?
No. Nothing has changed. Before any of these peptides may be compounded under 503A, the FDA must complete notice-and-comment rulemaking, which includes publishing a proposed rule, taking public comment, and issuing a final rule. That process can take 12 months or more, and the outcome is not predetermined.
Why did the committee vote differently from the FDA's own staff?
FDA's pre-meeting briefing documents recommended against adding all seven peptides, citing gaps in characterization, effectiveness and safety data. The committee nonetheless voted favorably on six of them. Advisory committees are convened precisely so that outside experts can reach their own conclusions, and they sometimes diverge from agency reviewers. The divergence is one reason the eventual FDA decision remains genuinely open.
Which peptide was not recommended?
Emideltide, also known as DSIP or delta sleep-inducing peptide, was the one substance of the seven that the committee did not recommend for addition to the 503A Bulks List.
How long until there is a final answer?
There is no fixed deadline. The FDA must work through the rulemaking process described above, and that commonly takes 12 months or more from the point of an advisory committee recommendation. Anyone offering a specific date, or presenting the outcome as already decided, is speculating.
This article is educational and regulatory in nature and is not medical advice. BPC-157, TB-500, Semax, MOTS-c, KPV, epitalon and emideltide are research peptides and are not FDA-approved for any human use. A July 2026 PCAC vote is an advisory recommendation only; a final FDA decision is pending and no change in legal compounding status has taken effect. Compounded medications are not FDA-approved and are prepared under federal and state compounding regulations. Any prescription requires review by a US-licensed provider, and approval is not guaranteed. Individual results vary. TelosRX is LegitScript-certified and operates as an online-first, asynchronous telehealth service.